LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY

By LabMedica International staff writers
Posted on 01 Aug 2014
Atomo Diagnostics (Melbourne, Australia) showcased integrated rapid blood test device to the USA market at the 2014 AACC Annual Meeting and Clinical Lab Expo, following a successful presentation at the 20th International AIDS Conference 2014 in Melbourne (Australia). The AtomoRapid all-in-one blood test can accommodate test strips for a wide variety of conditions from celiac disease and allergy through to infectious diseases such as malaria and human immunodeficiency virus (HIV).

The device delivers better clinical outcomes for patients and health care providers by enabling simpler, safer, and more accurate testing in the field or at home.

At AIDS 2014, Atomo Diagnostics participated in a conference session organized by the World Health Organization (WHO; Basel, Switzerland). The session focused on opportunities and challenges facing self-testing and a debate about real world situations. The AtomoRapid all-in-one blood test, which is half the size of an iPhone, has been deployed in South Africa for HIV and malaria testing, and clinical activities are in process in the EU and in planning in Asia and the USA.

Former ResMed executive and Atomo Diagnostics’ founder and CEO John Kelly MSc, BEng, comments: ”We have started with HIV and malaria because that was where false negatives and false positives from other existing ‘bits in a box’ products, which were sometimes greater than 10% when used in the field, were having the most significant impact on individuals.”

AtomoRapid HIV could play a significant role in supporting the Australian Government’s initiative to lift restrictions on home HIV testing. Around 30% of Australians with HIV are diagnosed well after they should have started treatment to restore their damaged immune system, according to the latest Annual HIV Surveillance report from the UNSW’s Kirby Institute (Sydney, Australia) Annual Symposium.

John Kelly adds, "We have seen from our work with the Desmond Tutu HIV Foundation in South Africa that if you want to be accepted as an at-home test you need an integrated intuitive solution that reduces test errors." Kelly was inspired to find a better way to test blood when his daughter developed a childhood disease requiring regular blood draws for diagnostic tests.

Given its ease of use and simplicity, AtomoRapid has the ability to materially improve both the uptake and reliability of testing in the community and at home. The company is currently implementing its plans to launch the product in Australia, the US, and Europe for both professional and at home use.

Over 100 million rapid HIV tests are bought each year globally, and Atomo Diagnostics is leading the transition to more user friendly all-in-one solution with its AtomoRapid innovation.

AtomoRapid took the top international medical technology award last month in New York at the Medical Design Excellence Awards and has been given a number of other important honors.

Related Links:

Atomo Diagnostics
World Health Organization
Kirby Institute


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more